Clozapine exerts its antipsychotic effects primarily through antagonism of serotonin (5-HT₂A) and dopamine (D₂) receptors. It is effective against both the positive and negative symptoms of schizophrenia while exhibiting a significantly lower incidence of extrapyramidal side effects.

Clinically, clozapine is reserved for patients with schizophrenia who are refractory to treatment with conventional antipsychotics. Due to the risk of inducing agranulocytosis, it is strictly designated as a second-line therapy and requires intensive hematological monitoring.

AccuSift provides high-performance competitive antibody pairs for clozapine detection. These reagents offer exceptional inter-batch consistency and are optimized specifically for IVD kit development, including lateral flow assays, chemiluminescence, ELISA, and POCT platforms. Featuring high affinity and high specificity, they enable rapid and reliable detection.

Sensitivity: ELISA LOD: 5 ng/mL